May 22, 2023 03:41 PM EDTUpdated 04:12 PM
R&D
Pharma

One-fifth of late-stage can­cer tri­als changed pri­ma­ry end­points af­ter tri­al start, JA­MA Net­work Open study says

Paul Schloesser

Associate Editor

Near­ly 20% of Phase III clin­i­cal tri­als for can­cer ther­a­pies had their pri­ma­ry end­points changed af­ter be­ing pub­licly re­port­ed, ac­cord­ing to a study

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times